data
collect
analysi
coordin
chines
nation
health
famili
plan
commiss
subject
includ
studi
patient
laboratoryconfirm
infect
diagnos
april
march
studi
subject
expand
cohort
hospit
infect
patient
pneumonia
april
previous
analyz
assess
impact
corticosteroid
upon
mortal
shed
electron
medic
record
patient
sent
data
collect
center
beij
china
demograph
data
comorbid
vital
sign
laboratori
find
admiss
virolog
test
result
treatment
review
train
team
physician
medic
student
enter
duplic
computer
databas
note
previous
collect
data
infect
patient
determin
compris
public
health
surveil
china
institut
review
board
assess
waiv
infect
confirm
patient
test
respiratori
specimen
realtim
revers
chain
reaction
rtpcr
assay
local
laboratori
chines
center
diseas
control
prevent
respiratori
specimen
nasopharyng
swab
specimen
sputum
specimen
endotrach
aspir
bronchoalveolar
lavag
fluid
collect
daili
detect
rna
realtim
rtpcr
detail
laboratori
confirm
describ
previous
respiratori
specimen
cycl
threshold
ct
valu
consid
posit
ct
valu
underw
repeat
test
upon
repeat
test
respiratori
specimen
ct
valu
consid
posit
ct
valu
undetect
result
consid
neg
defin
interv
symptom
onset
date
last
result
respiratori
sampl
rna
shed
durat
corticosteroid
treatment
defin
administr
dose
equival
mg
methylprednisolon
per
day
hospit
mean
valu
standard
deviat
median
valu
interquartil
rang
use
describ
continu
variabl
absolut
rel
frequenc
use
describ
categor
variabl
use
student
test
mannwhitney
u
test
analysi
continu
variabl
test
fisher
exact
test
analysi
discret
variabl
bivari
analys
identifi
risk
factor
associ
prolong
durat
rna
shed
perform
timedepend
cox
proport
hazard
model
adjust
baselin
covari
outcom
defin
time
rna
neg
analysi
censor
patient
never
clear
rna
discharg
aliv
clear
rna
hospit
discharg
analysi
perform
use
margin
structur
cox
proport
hazard
model
candid
variabl
consid
analysi
prolong
durat
shed
sex
age
comorbid
smoke
time
ill
onset
start
antivir
treatment
specif
antivir
nai
use
kaplanmei
surviv
analysi
estim
cumul
rate
stratifi
logrank
statist
compar
differ
clearanc
differ
group
ie
patient
survivor
vs
die
patient
start
nai
treatment
day
ill
onset
vs
start
nai
treatment
day
ill
onset
patient
receiv
oseltamivir
vs
receiv
combin
oseltamivir
plu
peramivir
patient
receiv
standarddos
oseltamivir
vs
receiv
doubledos
oseltamivir
statist
analys
perform
use
spss
version
window
ibm
armonk
ny
sa
version
sa
institut
cari
nc
analys
probabl
p
valu
consid
signific
median
durat
rna
shed
day
interquartil
rang
iqr
day
patient
realtim
rtpcr
confirm
infect
undetect
rna
within
day
test
neg
within
day
test
neg
within
day
ill
onset
rna
undetect
among
patient
within
day
symptom
onset
detect
small
subset
patient
day
symptom
onset
figur
supplementari
tabl
median
durat
shed
detect
endotrach
aspir
specimen
day
iqr
day
similar
median
durat
shed
detect
nasopharyng
swab
day
iqr
day
hazard
ratio
hr
confid
interv
ci
p
supplementari
figur
viral
rna
clearanc
significantli
faster
survivor
compar
fatal
case
hr
ci
p
figur
multivari
model
includ
avail
data
patient
time
ill
onset
antivir
treatment
hr
ci
system
corticosteroid
administr
hr
ci
independ
factor
associ
durat
rna
shed
tabl
figur
similar
risk
factor
delay
rna
clearanc
observ
data
analyz
use
margin
structur
cox
proport
hazard
model
supplementari
tabl
median
time
ill
onset
nai
treatment
initi
day
iqr
day
rna
clearanc
significantli
delay
patient
receiv
nai
treatment
begin
day
ill
onset
compar
nai
treatment
start
day
ill
onset
hr
ci
p
figur
among
patient
antivir
treatment
administ
includ
oseltamivir
monotherapi
peramivir
oseltamivir
peramivir
zanamivir
oseltamivir
oseltamivir
ribavirin
oseltamivir
ganciclovir
median
durat
shed
day
rang
day
oseltamivir
monotherapi
group
day
rang
day
oseltamivirperamivir
combin
treatment
group
main
characterist
patient
receiv
differ
antivir
drug
summar
tabl
median
time
antivir
treatment
initi
neg
realtim
rtpcr
result
respiratori
tract
specimen
day
rang
day
oseltamivir
monotherapi
group
day
rang
day
oseltamivirperamivir
combin
therapi
group
p
signific
differ
durat
rna
shed
patient
receiv
oseltamivir
monotherapi
compar
receiv
oseltamivirperamivir
combin
therapi
figur
oseltamivir
dose
data
avail
patient
differ
rna
clearanc
hr
ci
p
figur
inhospit
mortal
respect
p
tabl
patient
receiv
oseltamivir
twicedaili
treatment
receiv
twicedaili
treatment
compar
proport
patient
test
posit
rna
time
start
nai
treatment
use
logrank
test
signific
differ
among
patient
receiv
standarddos
oseltamivir
doubledos
oseltamivir
oseltamivir
peramivir
treatment
hr
ci
p
supplementari
figur
report
largest
cohort
hospit
patient
infect
china
date
studi
expand
prior
studi
hospit
infect
patient
pneumonia
report
associ
highdos
corticosteroid
therapi
increas
mortal
longer
durat
rna
detect
current
studi
hospit
infect
patient
identifi
independ
risk
factor
prolong
rna
detect
examin
impact
differ
antivir
treatment
regimen
rna
shed
patient
nai
treatment
start
hour
ill
onset
initi
nai
treatment
fifth
day
ill
associ
shorter
durat
rna
shed
combin
antivir
treatment
differ
nai
doubledos
oseltamivir
associ
signific
differ
rna
shed
inhospit
mortal
compar
standarddos
oseltamivir
monotherapi
detect
rna
respiratori
tract
median
day
prolong
rna
shed
associ
fatal
outcom
data
durat
highli
pathogen
avian
influenza
viru
shed
limit
indic
rna
detect
longer
higher
level
lower
respiratori
tract
tissu
includ
day
fatal
case
upper
respiratori
tract
specimen
systemat
review
report
progress
longer
shed
durat
patient
correl
diseas
sever
studi
stratifi
commun
rang
mean
median
valu
day
hospit
rang
mean
median
valu
day
intens
care
rang
mean
median
valu
day
set
detect
rna
day
patient
receiv
corticosteroid
dose
least
mgday
mg
prednisoneday
consid
immunosuppress
dose
supplementari
tabl
influenza
viral
rna
detect
respiratori
tract
particularli
lower
respiratori
tract
prolong
period
patient
sever
diseas
immunosuppress
ill
onset
better
understand
kinet
influenza
viru
replic
upper
lower
respiratori
tract
infect
patient
would
use
futur
studi
delay
initi
nai
treatment
independ
risk
factor
associ
prolong
rna
shed
similarli
singlecent
retrospect
studi
zheng
et
al
report
rna
shed
significantli
shorter
nai
treatment
start
within
day
ill
onset
antivir
treatment
start
later
median
time
ill
onset
nai
treatment
initi
day
among
patient
studi
earlier
administr
nai
treatment
might
reduc
viral
shed
improv
surviv
infect
patient
larg
metaanalysi
individuallevel
data
patient
hospit
infect
report
earli
day
versu
later
day
initi
nai
treatment
significantli
associ
surviv
benefit
adult
later
initi
nai
treatment
significantli
associ
lower
mortal
risk
compar
treatment
find
also
suggest
nai
treatment
start
earli
possibl
infect
suspect
without
wait
virolog
confirm
corticosteroid
therapi
commonli
administr
critic
ill
patient
influenza
reduc
cytokin
dysregul
lung
inflamm
improv
clinic
outcom
howev
observ
studi
report
use
corticosteroid
associ
persist
viral
shed
patient
season
influenza
middl
east
respiratori
syndrom
sever
acut
respiratori
syndrom
addit
previou
observ
studi
use
propensityscor
match
show
use
highdos
corticosteroid
associ
fatal
outcom
among
patient
pneumonia
infect
result
accord
find
corticosteroid
treatment
highdos
corticosteroid
dose
associ
prolong
viral
shed
durat
prolong
viral
shed
associ
fatal
outcom
mechan
delay
viral
clearanc
due
corticosteroid
treatment
well
defin
might
associ
impair
tcell
respons
taken
togeth
find
suggest
corticosteroid
given
treatment
infect
anoth
potenti
reason
prolong
durat
viral
rna
shed
emerg
nai
resist
antivir
treatment
hu
et
al
report
emerg
oseltamivirresist
viru
mutat
gene
encod
viral
neuraminidas
infect
patient
nai
treatment
tempor
associ
rebound
load
treatment
failur
mutat
confer
resist
oseltamivir
highli
reduc
inhibit
peramivir
zanamivir
vitro
suggest
nai
treatment
would
effect
treat
infect
virus
contain
mutat
concern
preval
mutat
increas
sinc
first
human
infect
report
approxim
among
sequenc
virus
infect
patient
fifth
epidem
recent
ke
et
al
describ
detect
mutat
earli
day
start
oseltamivir
treatment
patient
highli
pathogen
infect
studi
first
assess
impact
differ
nai
regimen
includ
combin
treatment
differ
dosag
oseltamivir
viral
shed
clinic
outcom
patient
infect
find
doubledos
oseltamivir
provid
addit
virolog
benefit
compar
standarddos
oseltamivir
treatment
consist
result
control
trial
outpati
inpati
season
influenza
observ
studi
hospit
patient
infect
previou
studi
suggest
reason
observ
oseltamivir
gener
well
absorb
rapidli
convert
activ
compound
oseltamivir
carboxyl
bioavail
blood
concentr
oseltamivir
carboxyl
associ
singl
doubledos
therapi
patient
influenza
exceed
median
inhibitori
concentr
ie
ngml
influenza
virus
exceed
concentr
might
produc
addit
clinic
virolog
effect
addit
may
delay
antivir
treatment
sever
diseas
alreadi
present
may
reduc
potenti
benefit
doubledos
oseltamivir
retrospect
analysi
limit
number
patient
infect
report
oseltamivir
plu
peramivir
superior
oseltamivir
monotherapi
clinic
virolog
outcom
clinic
data
includ
random
trial
combin
oseltamivir
zanamivir
treatment
compar
either
monotherapi
alon
season
influenza
substanti
potenti
advantag
use
combin
nai
rather
data
appear
consist
show
use
combin
target
protein
show
addit
synergist
effect
influenza
viru
infect
studi
sever
limit
first
studi
limit
retrospect
natur
dose
antivir
miss
patient
first
epidem
second
patient
laboratoryconfirm
infect
mainland
china
could
includ
studi
howev
abl
includ
patient
manag
differ
hospit
third
owe
small
number
patient
initi
nai
treatment
day
ill
onset
abl
assess
effect
earli
versu
later
initi
nai
treatment
fourth
genet
sequenc
perform
specimen
patient
prolong
durat
rna
shed
assess
frequenc
emerg
antivir
resist
therefor
possibl
analyz
relationship
antivir
resist
prolong
shed
sinc
pair
upper
lower
respiratori
tract
specimen
collect
prospect
patient
could
directli
compar
differ
viral
shed
upper
ie
nasopharyng
swab
specimen
versu
lower
endotrach
aspir
respiratori
tract
specimen
howev
find
signific
differ
durat
shed
nasopharyng
swab
specimen
endotrach
aspir
conclus
prolong
rna
shed
respiratori
tract
independ
associ
delay
initi
nai
treatment
use
corticosteroid
result
reinforc
guidanc
nai
treatment
start
soon
possibl
patient
suspect
infect
suggest
corticosteroid
avoid
except
clinic
situat
proven
benefit
although
prospect
random
control
studi
need
definit
assess
clinic
virolog
benefit
combin
nai
therapi
higher
dose
oseltamivir
find
observ
studi
suggest
benefit
higher
oseltamivir
dose
use
multipl
nai
treatment
infect
patient
increas
frequenc
emerg
resist
nai
treatment
high
casefat
proport
indic
urgent
need
improv
antivir
treatment
strategi
includ
drug
differ
mechan
action
nai
use
combin
nai
hospit
patient
infect
ideal
avail
new
drug
evalu
context
random
control
trial
infect
patient
